To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter

Inclusion Criteria: * Are willing and able to give informed consent * Have CCS class III or IV angina refractory to optimized medical therapy * Experience signs or symptoms of angina during the exercise tolerance test (ETT) * Have identified area(s) of reversible ischemic myocardium * Have procedurally acceptable targeted treatment zones Exclusion Criteria: * Have exercise-limited non-cardiac chest discomfort * Unwilling or unable to undergo exercise testing * Able to exercise greater than 6 minutes on the treadmill * Are candidates for conventional revascularization procedures * Are or have been enrolled within 30 days, in another experimental study * Have had the most recent angiogram more than 6 Months prior to screening * Previously received an investigational angiogenic agent * Have another disease severe enough to limit exercise test or place patient at risk * Have uncontrolled: atrial fibrillation, atrial flutter, and/or significant arrhythmias * Have evidence of left ventricular aneurysm or ventricular thrombus * Are unwilling or unable to undergo cardiac catheterization or nuclear testing procedures * Have had a Q-wave MI, within 60 days * Have severe aortic valve stenosis or have a mechanical aortic or mitral valve * Have unstable angina or an acute non-Q-wave myocardial infarction within 14 days * Have had a documented stroke or transient ischemic attack within 60 days * Are pacemaker dependent * Have a recent history of active diabetic retinopathy or age-related wet macular degeneration * Have a history of cancer within the last 5 yrs. or have current evidence of a malignant neoplasm * Have a history of alcohol or drug abuse within 90 days * Are pregnant or lactating * Have reproductive potential and are unwilling to use condoms for contraception for 1 year after treatment - both male and female * Are unable to return to the clinic for the scheduled follow-up appointments * Are taking medications which may produce an undue risk * Have areas of LV wall less than 6mm thick